A Study Evaluating GDC-0980 Administered Once Daily in Patients With Refractory Solid Tumors or Non-Hodgkin's Lymphoma
Status:
Completed
Trial end date:
2014-11-01
Target enrollment:
Participant gender:
Summary
This is an open-label, multicenter, Phase I study to evaluate the safety, tolerability, and
pharmacokinetics of escalating oral doses of GDC-0980 administered to patients with
incurable, locally advanced or metastatic solid malignancy or NHL that has progressed or
failed to respond to at least one prior regimen or for which there is no standard therapy.